| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/40-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | NACHRA9; HSA243342 |
| WB Predicted band size | 55 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Rat |
| Immunogen | Synthetic peptide of human CHRNA9 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇与CHRNA9抗体相关的参考文献(基于公开数据概括，非真实文献)：
1. **"CHRNA9-specific monoclonal antibody characterization in auditory pathway studies"**
- 作者：L. Müller et al.
- 摘要：开发并验证了一种针对CHRNA9亚基的单克隆抗体，用于检测内耳毛细胞和中枢听觉通路中该受体的表达模式，揭示了其在听觉信号传导中的作用。
2. **"Targeting CHRNA9 with therapeutic antibodies in head and neck cancer"**
- 作者：R. Gupta & T. Patel
- 摘要：研究报道了一种人源化抗CHRNA9抗体，通过抑制受体介导的促癌信号通路，在头颈癌临床前模型中显示出抗肿瘤活性。
3. **"CHRNA9 antibody-based detection in neuroendocrine tumors"**
- 作者：S. Yamamoto et al.
- 摘要：利用CHRNA9特异性抗体进行免疫组化分析，发现该受体在部分神经内分泌肿瘤中高表达，提示其作为潜在诊断标志物的价值。
注：以上内容为示例性概括，实际文献需通过PubMed或Google Scholar以关键词“CHRNA9 antibody”检索确认。
The CHRNA9 antibody targets the alpha-9 subunit of the nicotinic acetylcholine receptor (nAChR), encoded by the *CHRNA9* gene. This subunit forms ligand-gated ion channels, primarily in non-neuronal tissues, and plays a critical role in auditory function, inflammation modulation, and cellular signaling. CHRNA9 is notably expressed in the cochlea, where it contributes to hair cell development and sound transduction. Dysregulation of CHRNA9 is linked to hearing disorders, including age-related and noise-induced hearing loss.
Beyond auditory pathways, CHRNA9 is involved in immune regulation, influencing cytokine release and immune cell activity. Its aberrant expression has been observed in cancers (e.g., breast, lung) and autoimmune diseases, suggesting roles in tumor progression and inflammation. CHRNA9 antibodies are essential tools for studying receptor localization, expression patterns, and functional interactions in both physiological and pathological contexts.
Researchers use these antibodies in techniques like Western blotting, immunohistochemistry, and flow cytometry to explore CHRNA9's role in cellular signaling, disease mechanisms, and therapeutic targeting. Recent studies also investigate CHRNA9's potential as a biomarker or drug target for hearing disorders and cancer immunotherapy. Despite its niche focus, CHRNA9 research highlights the receptor's diverse impact across sensory, immune, and oncological systems.
×
